Cited by 49Bone Tumor Diagnosis and TreatmentsSarcoma Diagnosis and TreatmentCancer, Hypoxia, and Metabolism

Development and characterization of a human three-dimensional chondrosarcoma culture for in vitro drug testing

Open access
Voissiere, Aurélien, Jouberton, Elodie, Maubert, Elise, Degoul, Françoise, Peyrode, Caroline, Chezal, Jean-Michel, Miot-Noirault, Élisabeth·2017·PLOS ONE

Abstract

It has been suggested that chemoresistance of chondrosarcoma (CHS), the cartilage tumor, is caused by the phenotypic microenvironmental features of the tumor tissue, mainly the chondrogenic extracellular matrix (ECM), and hypoxia. We developed and characterized a multicellular tumor spheroid (MCTS) of human chondrosarcoma HEMC-SS cells to gain insight into tumor cell biology and drug response. At Day 7, HEMC-SS spheroids exhibited a homogeneous distribution of proliferative Ki-67 positive cells, whereas in larger spheroids (Day 14 and Day 20), proliferation was mainly localized in the periphery. In the core of larger spheroids, apoptotic cells were evidenced by TUNEL assay, and hypoxia by pimonidazole staining. Interestingly, VEGF excretion, evidenced by ELISA on culture media, was detectable from Day 14 spheroids, and increased as the spheroids grew in size. HEMC-SS spheroids synthesized a chondrogenic extracellular matrix rich in glycosaminoglycans and type-2 collagen. Finally, we investigated the sensitivity of Day 7 and Day 14 chondrosarcoma MCTS to hypoxia-activated prodrug TH-302 and doxorubicin compared with their 2D counterparts. As expected, TH-302 exhibited higher cytotoxic activity on larger hypoxic spheroids (Day 14) than on non-hypoxic spheroids (Day 7), with multicellular resistance index (MCRI) values of 7.7 and 9.1 respectively. For doxorubicin, the larger-sized spheroids exhibited higher drug resistance (MCRI of 5.0 for Day 7 and 18.3 for Day 14 spheroids), possibly due to impeded drug penetration into the deep layer of spheroids, evidenced by its auto-fluorescence property. We have developed a model of human chondrosarcoma MCTS that combines an ECM rich in glycosaminoglycans with a high hypoxic core associated with VEGF excretion. This model could offer a more predictive in vitro chondrosarcoma system for screening drugs targeting tumor cells and their microenvironment.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0181340

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Fluorescently labeled antibodies targeting caspase-3, Ki-67, and hypoxia-inducible factors, or exogenous hypoxia indicators such as pimonidazole and EF5, allow visualization of apoptotic, proliferating, or hypoxic regions, respectively.

    “Fluorescently labeled antibodies targeting markers such as caspase-3, Ki-67, and hypoxia-inducible factors, or exogenous hypoxia indicators such as pimonidazole and EF5, allow visualization of apoptotic, proliferating, or hypoxic regions, respectively [235,236].”

    From Modeling Tumor Microenvironment Complexity In Vitro: Spheroids as Physiologically Relevant Tumor Models and Strategies for Their Analysis (2025) · cites this paper as [235]

    The Methods and Results sections report fluorescent Ki-67 staining to locate proliferating cells and pimonidazole staining to locate hypoxic regions in chondrosarcoma spheroids (page numbers unavailable). They locate apoptotic cells using TUNEL, not a caspase-3 antibody. The paper does not report using hypoxia-inducible-factor antibodies or EF5 for visualization. (LLM, conf=0.88)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 42 · Cited by 49

Authors
Voissiere, A., Jouberton, E., Maubert, E., Degoul, F., Peyrode, C., Chezal, J.-M., & Miot-Noirault, É.
Affiliations
Inserm (FR)
Venue
PLOS ONE
Published
2017-07-13
Volume
12
Issue
7
Pages
e0181340
ISSN
1932-6203 (ISSN-L)
OpenAlex
W2735181486
Cited by
49
References
42
Citations by year
2026: 2 · 2025: 5 · 2024: 1 · 2023: 4 · 2022: 6 · 2021: 10 · 2020: 15 · 2019: 3 · 2018: 2 · 2017: 1
FWCI
5.02
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • HAL (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Ligue Contre le Cancer
  • Institut National Du Cancer (PRT-k, Translational Cancer Research: INCa-DGOS, D-TECT project reference R15066CC / RPT15003CCA)
Topics
  • Health Sciences › Medicine › Rheumatology › Bone Tumor Diagnosis and Treatments
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Sarcoma Diagnosis and Treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
Keywords
chondrosarcoma, tumor spheroids, chemoresistance, hypoxia, extracellular matrix, glycosaminoglycans, type II collagen, vascular endothelial growth factor, TH-302, doxorubicin, drug penetration, tumor microenvironment, Ki-67, apoptosis, in vitro drug testing
MeSH terms
Antineoplastic Agents, Bone Neoplasms, Chondrosarcoma, Doxorubicin, Drug Screening Assays, Antitumor, Humans, Nitroimidazoles, Phosphoramide Mustards, Spheroids, Cellular, Cell Culture Techniques, Cell Line, Tumor, Cell Proliferation, Tissue Scaffolds

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review